Replies to post #494147 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The publication's peer reviewers do not have access to data other than that included in the paper.

The few key folks who actually wrote the paper may have had access to raw data. The analysis of the raw data according to Anavex was performed by external consultants, not inhouse e.g. Dr. Jin or anyone else working at Anavex.

The long list of names in the paper is because their work contributed clinical data from their respective sites. They will have seen the paper based on that data, but they are unlikely to have had access to the full consolidated trials data across all clinical trial sites.

I am not assuming that the external consultants have cooked the data or know what directions they have been given and how much finessing can or has been do to the external consultant's analysis output, when write the paper for peer review. This is what he CHMP will have to evaluated and they will.

[xodcode]

That Dr. Jin would be duplicitous in a scheme seems almost impossible .

No matter how ridiculous such a suggestion is, it's fair game for some of the naysayers. Any negative twist, no matter how unreasonable, is part of their schtick.

Very highly probable that positive Schizophrenia results and EMA Blarcamesine approval await the patient AVXL investor as does a much higher AVXL share price.

Interesting how the naysayers petulance increases the closer we get to AVXL news.

Shut out the negative noise and enjoy the ride!

And, oh yes, by the way, WGT!